Dapagliflozin (CKD) — Membership Pricing

Other medications in Diabetes & Metabolism

• Dulaglutide
• Empagliflozin
• Etelcalcetide
• Exenatide
• Finerenone
• Glimepiride
• Glipizide
• Glyburide

About Dapagliflozin (CKD)

Dapagliflozin, often prescribed for chronic kidney disease (CKD), plays a crucial role in managing this condition. Understanding your medication is important, and so is managing its cost. TheDrugClub is dedicated to helping members like you find significant savings on essential prescriptions, including dapagliflozin, making your health journey more affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Dapagliflozin (CKD) is approved for (FDA label)

Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular (CV) disease or multiple CV risk factors. As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Source: Read the full FDA label on DailyMed. Label effective date: September 8, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dapagliflozin (CKD) (FDA label)

Tablets: 5 mg, are yellow, film-coated, round tablets, debossed with "TV" on one side, and “5D” on the other side. 10 mg, are yellow, film-coated, oval tablets, debossed with "TV" on one side, and “1D” on the other side. Tablets: 5 mg and 10 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 05c3cf00-8c2a-4227-958a-fa5db34512b0. SPL document ID: 07037872-7796-4714-81ad-2a7a114d3a13. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dapagliflozin (CKD) (FDA label)

The following important adverse reactions are described below and elsewhere in the labeling: Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precautions ( 5.1 )] Volume Depletion [see Warnings and Precautions ( 5.2 )] Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections [see Warnings and Precautions ( 5.3 )] Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues [see Warnings and Precautions ( 5.4 )] Most common adverse reactions (5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 05c3cf00-8c2a-4227-958a-fa5db34512b0. SPL document ID: 07037872-7796-4714-81ad-2a7a114d3a13. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dapagliflozin (CKD) (FDA label)

Dapagliflozin is contraindicated in patients with a history of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in dapagliflozin. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with dapagliflozin [see Adverse Reactions ( 6.1 )] . History of serious hypersensitivity reaction to dapagliflozin or any of the excipients in dapagliflozin. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 05c3cf00-8c2a-4227-958a-fa5db34512b0. SPL document ID: 07037872-7796-4714-81ad-2a7a114d3a13. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dapagliflozin (CKD) (FDA label)

Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis: Consider ketone monitoring in patients with type 1 diabetes mellitus and consider ketone monitoring in others at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue dapagliflozin if ketoacidosis is suspected. Monitor patients for resolution of ketoacidosis before restarting. ( 5.1 ) Volume depletion: Before initiating dapagliflozin, assess volume status and renal function in the elderly, patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy. ( 5.2 ) Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections: Monitor patients for signs and symptoms of genitourinary infections and treat promptly, if indicated.

Source: FDA prescribing information (DailyMed). Set ID: 05c3cf00-8c2a-4227-958a-fa5db34512b0. SPL document ID: 07037872-7796-4714-81ad-2a7a114d3a13. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Dapagliflozin (CKD) (FDA label)

Table 4: Clinically Relevant Interactions with Dapagliflozin Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when dapagliflozin is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions ( 5.4 )] . Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during dapagliflozin initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Intervention Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

Source: FDA prescribing information (DailyMed). Set ID: 05c3cf00-8c2a-4227-958a-fa5db34512b0. SPL document ID: 07037872-7796-4714-81ad-2a7a114d3a13. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.